Dr. Reddy’s Laboratories (DRREDDY) M&A Announcement summary

Deal rationale and strategic fit

• Acquisition of a global consumer healthcare portfolio in Nicotine Replacement Therapy (NRT), including Nicotinell and related brands, aligns with the strategy to expand in consumer healthcare and OTC wellness products, strengthening presence in 30+ countries outside the US.

• The acquired brands are market leaders outside the U.S., with Nicotinell holding leading positions in 14 of the top 17 markets and among the top 15 OTC brands in Europe.

• The deal complements the existing OTC business, serving as an anchor for future product additions and market entries, especially in Asia.

• The acquisition leverages established relationships with key customers and retailers, facilitating cross-selling and broader market access.

• Provides access to established brands with strong customer loyalty and global reach, supporting further OTC platform growth.

Financial terms and conditions

• Total consideration is GBP 500 million: GBP 458 million upfront and up to GBP 42 million in earn-outs or performance-based contingent payments due in 2025 and 2026.

• The portfolio generated GBP 217 million in revenue in 2023 and is described as healthy and marginally accretive.

• The transaction will be funded through internal accruals.

Synergies and expected cost savings

• Main synergies expected from leveraging the platform to introduce additional products and expand into new markets.

• Cross-selling opportunities and operating leverage anticipated as the business grows and more brands are added.